ADVERTISING FEATURE
Immunoassay analyser boasts elite performance with no daily maintenance
The innovations included in Beckman Coulter Diagnostics’ new DxI 9000 Access Immunoassay Analyzer bolster assay performance and laboratory productivity with new analyte processing and detection technology, remote real-time system monitoring, and all with no daily maintenance.
Clinical diagnostics leader Beckman Coulter has unveiled the DxI 9000 Access Immunoassay Analyzer, the most productive immunoassay analyser per footprint, with the ability to run up to 215 tests per hour per square meter (tests/hr/m2
).
The DxI 9000 has been designed to meet today’s speed, reliability, reproducibility, quality, and menu expansion demands. The platform has been independently verified to perform at the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) optimal level, the highest level of EFLM performance evaluation. At the same time, the novel Lumi-Phos PRO Substrate has shown the capability to develop increasingly sensitive and clinically relevant assays, ensuring the system is able to meet the healthcare needs of tomorrow.
The new analyser was officially unveiled at EuroMedLab 2023 in Rome at the end of May. According to Julie Sawyer Montgomery, President, Beckman Coulter Diagnostics: “The DxI 9000 Access Immunoassay Analyzer sets new expectations for immunoassay testing operational performance and ability to develop and sustain improved assay sensitivity to meet tomorrow’s analytical needs. Those in the laboratory will treasure ZeroDaily Maintenance to save them time, PrecisionVision
6
Technology to safeguard against flawed data reports, and IntelliServe to maximise system uptime. At the same time, clinical researchers are excited about the DxI 9000’s capability to keep pace with increasingly sensitive testing requirements as healthcare providers and pharmaceutical companies take aim at ever more challenging diseases. An inspiring feat of technology, the DxI 9000 Analyzer is a comprehensive healthcare innovation.”
Key features ZeroDaily Maintenance highlights the embedded innovations that drive the DxI 9000’s uptime performance. Early adopters attest to ZeroDaily Maintenance redefining their workday with no daily maintenance requirements, thereby reducing annual maintenance routines by up to 96%.
Building on Beckman Coulter’s workflow and automation leadership, PrecisionVision Technology has the ability to inspect, identify and prevent erroneous reporting in real time. PrecisionVision automated safeguards include tube identification, cap detection, tip check, sample aspiration, and delivery, residual wash volume, and substrate volume. Each check reduces the risk of reporting flawed data and increases system reliability and reproducibility.
Beckman Coulter’s newly designed
Beckman Coulter’s DxI 9000 Access Immunoassay Analyzer has been independently verified to perform at the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) optimal level, the highest level of EFLM performance evaluation.
remote service and diagnostics solution, DxS IntelliServe, connects with the DxI 9000 to monitor data and error trends, enabling timely, proactive system service when needed. In addition, the DxS IntelliServe solution identifies service experts to resolve issues with real-time monitoring, remote operation, and troubleshooting to maximise laboratory uptime and performance. Equally impactful, IntelliServe’s remote update capabilities and proactive scheduling ensures systems are always running on the most up-to-date software, reducing unplanned workflow interruptions or downtime.
JUNE 2023
WWW.PATHOLOGYINPRACTICE.COM
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56
